Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Candidate PCV13 in Healthy People
NCT05602480Phase 1Unknown
- Sponsor
- Wuhan BravoVax Co., Ltd
- Start
- Nov 2022
- Primary completion
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 13-valent pneumococcal polysaccharide conjugate vaccine in pneumococcal infection (10 arms), sponsored by Wuhan BravoVax Co., Ltd. Primary endpoints: Safety in terms of adverse reactions, Safety in terms of adverse events and 2 more. Status: unknown.
02
Drugs
13-valent pneumococcal polysaccharide conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT05602480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05602480.